Trimeric OX40-immunoglobulin fusion protein and methods of use

Details Trimeric OX40-immunoglobulin fusion protein and methods of use Trimeric OX40-immunoglobulin fusion protein and methods of use

2011-06-14

2011-06-14

Shafer, Shulamith H (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S178100, C424S179100, C424S185100, C424S195110, C424S198100, C530S387300, C530S388220, C530S388750, C536S023400, C536S023530

Reexamination Certificate

active

07959925

ABSTRACT:
Compositions including a trimeric OX-40 fusion protein are disclosed. Also disclosed are methods for enhancing the immune response of a mammal to an antigen by engaging the OX-40 receptor on the surface of T-cells involving administering to the mammal a composition comprising a trimeric OX-40 fusion protein and a pharmaceutically acceptable carrier.

REFERENCES:
patent: 5457035 (1995-10-01), Baum et al.
patent: 5525491 (1996-06-01), Huston et al.
patent: 5686564 (1997-11-01), Brundish et al.
patent: 5783665 (1998-07-01), Baum et al.
patent: 6242566 (2001-06-01), Godfrey et al.
patent: 6312700 (2001-11-01), Weinberg
patent: 6620413 (2003-09-01), DeSauvage et al.
patent: 6936439 (2005-08-01), Mann et al.
patent: 7179468 (2007-02-01), Lu et al.
patent: 7238499 (2007-07-01), Reddy
patent: 7271149 (2007-09-01), Glaesner et al.
patent: 2002/0054873 (2002-05-01), Weinberg
patent: 2003/0100027 (2003-05-01), Colyer et al.
patent: 2003/0119149 (2003-06-01), Reddy
patent: 2003/0224991 (2003-12-01), Dhanabal et al.
patent: 2004/0131587 (2004-07-01), Thomas et al.
patent: WO 95/12673 (1995-05-01), None
patent: WO 95/21915 (1995-08-01), None
McWhirter et al. 1999. PNAS 99:8408-8413.
Pullin et al. 1998. Biochem. 37:11836-11845.
Calderhead et al. “Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions,”J. Immunol., 151(10):5261-5271, 1993.
Gardnerova, et al., “The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents,”Current Drug Targets1:327-364, 2000.
Harbury et al. “A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants,”Science, 262(5138):1401-1407, 1993.
Haswell et al., “Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154,”Eur. J Immunol. 31:3094-3100, 2001.
International Search Report from related PCT Application No. PCT/US2006/017285, 4 pages, mailed Jan. 29, 2007.
Kelly et al., “Production of a Chimeric Form of CD23 that is Oligomeric and Blcoks IgE Binding to the FcβRI,”J. of Immunology, 161:6696-6704, 1998.
Latza et al. “The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen,”Eur. J. Immunol., 24(3):677-683, 1994.
Mallett et al. “Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes—a molecule related to nerve growth factor receptor,”EMBO J., 9(4):1063-1068, 1990.
Miura et al., “Molecular Cloning and Characterization of a Novel Glycoprotein, gp34, that is Specifically Induced by the Human T-Cell Leukemia Virus Type I Transactivator p40tax,” Molecular and Cellular Biology 11(3):1313-1325, Mar. 1991.
Morris et al.,J. Biol Chem, 274:418-423, 1999.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, 492-495, 1994.
Paterson et al. “Antigens of activated rat T lymphocytes including a molecule of 50,000 Mrdetected only on CD4 positive T blasts,”Mol. Immunol., 24(12):1281-1290, 1987.
Phillips,J. Pharm Pharmacology, 53:1169-1174, 2001.
Stark et al., “The use of trimeric isoleucine-zipper fusion proteins to study surface-receptor-ligand interactions in natural killer cells,”J. of Immunological Methods296:149-158, 2005.
Weinberg et al. “Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis,”Nature Medicine, 2(2):183-189, 1996.
Weinberg et al. “Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis,”J. Immunol., 152(9):4712-4721, 1994.
Weinberg et al., “Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity,”J. of Immunology, 164:2160-2169, 2000.
Weissenhorn et al., “Assembly of a rod-shaped chimera of a trimeric GCN4 zipper and the HIV-1 pg41 ectodomain expressed inEscherichia coli,” Proc. Natl. Acad. Sci. USA, 94:6065-6069, 1997.
Wells,Biochemistry, 29:8509-8517, 1990.
Morris et al., “Development and Characterization of Recombinant Human Fc:OX40L Fusion Protein Linked Via a Coiled-Coil Trimerization Domain,”Molecular Immunology44:3112-3121 (2007).

Affiliated with

Also associated with

Rating

Trimeric OX40-immunoglobulin fusion protein and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Trimeric OX40-immunoglobulin fusion protein and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trimeric OX40-immunoglobulin fusion protein and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2717208